Market accessOfficial

Methergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports

🇩🇰 DKMA · Fri 13 Nov 2026

Essential Pharma Limited has permanently stopped marketing Methergin solution for injection in Denmark from early November 2026, citing production problems, according to the Danish Medicines Agency.

The Danish Medicines Agency (DKMA) has published a supply notice saying that marketing of Methergin 0.2 mg/ml solution for injection from Essential Pharma Limited has ceased. The notice is dated 13 November 2026.

The product contains the active substance methylergometrine (ATC code G02AB01). DKMA gives the expected period of the supply difficulty as from the start of November 2026 and names production problems as the reason.

The agency describes the situation as a permanent withdrawal from the market. It does not name a replacement product or give details of the production issues. It directs questions about the current status to the company.

Methylergometrine is used in the management of obstetric haemorrhage, so the loss of a marketed injectable presentation may matter for hospital and obstetric supply planning.

What it means for your team

  • Supply-chain and QA teams should confirm whether any Methergin 0.2 mg/ml stock or contracts are affected and what alternatives are available in Denmark.
  • Regulatory teams should check DKMA's supply-notice pages for further updates, since the notice offers no alternative and points to the company for status questions.
  • Pharmacovigilance and medical information teams may wish to prepare for enquiries on switching, given the product's obstetric use.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →